PYC Therapeutics' VP-001 Receives Fast Track Designation from FDA
Australian Stock Exchange listed company PYC Therapeutics Limited (PYC) has made a significant advancement in the treatment of Retinitis Pigmentosa type 11 (RP11). The company announced that its VP-001 program, the first investigational drug candidate designed to address RP11, has been granted Fast Track designation by the US Food and Drug Administration (FDA).
The Fast Track process, designed to facilitate the development and review of drugs for serious conditions with unmet medical needs, offers numerous benefits for PYC's VP-001 program. Among these benefits are an increased frequency of meetings with the FDA to discuss the drug's development plan, eligibility for Accelerated Approval and Priority Review if relevant criteria are met, and the potential for a Rolling Review in support of a New Drug Application.
PYC plans to leverage the Fast Track designation to collaborate closely with the FDA and accelerate the development of VP-001, aiming to bring this crucial drug program to patients as quickly as possible.
Retinitis Pigmentosa Type 11 is a blinding eye disease that affects approximately one in every 100,000 people and typically begins in childhood, leading to legal blindness in middle age. The disease is caused by insufficient expression of the PRPF31 gene in the retina. Currently, there are no available treatment options for RP11, and no drugs are in clinical development.
VP-001, PYC's precision therapy, represents a potential breakthrough in addressing RP11. The therapy aims to restore the expression of the PRPF31 gene to normal levels, promoting the proper function of the retina. Utilizing PYC's proprietary drug delivery technology, VP-001 overcomes a significant challenge for RNA drugs by ensuring sufficient drug delivery to the targeted cells affected by RP11.
PYC’s CEO Dr. Rohan Hockings commented: "We welcome the opportunity to work with the FDA to progress this important drug candidate towards becoming the first treatment option available for patients with RP11 with disease-modifying potential”.
PYC Therapeutics is at the forefront of creating a new generation of RNA therapies to treat genetic diseases. Leveraging its proprietary drug delivery platform, the company enhances the potency of precision medicines within the rapidly growing RNA therapeutic class. By focusing on monogenic diseases, PYC's drug development programs are strategically aimed at indications with the highest likelihood of success in clinical development.
The VP-001 program's Fast Track designation marks a significant milestone in the development of potential treatment for RP11, bringing hope to patients with this debilitating condition. PYC Therapeutics is now progressing multiple 'fast-follower' programs into the clinic, continuing its commitment to changing the lives of patients with genetic diseases through cutting-edge research and drug development.
